Opinion statement
Generic antiepileptic drugs (AEDs) generally provide safe, effective, lower-cost alternatives to brand-name drugs. To be approved by the US Food and Drug Administration (FDA), manufacturers must show that generic drugs are comparable to brand-name formulations, meeting bioequivalence, dissolution, and manufacturing quality standards. Bioequivalence for most generic formulations is evaluated by measuring blood pharmacokinetic values in a small, crossover study of adult volunteers taking single doses of brand-name and generic AEDs. Bioequivalence standards require that ratios of average peak drug concentrations (Cmax) and total extent of absorption (area under the curve, AUC) for a test drug be within 80% to 125% of the reference brand-name drug, with a confidence interval of 90%. Bioequivalence of most generic AEDs, however, has not been evaluated in patients with epilepsy or in other special populations such as elderly patients or patients taking multiple AEDs and prodrugs. Moreover, evidence is limited regarding the adequacy of FDA generic standards for AEDs, particularly for “narrow therapeutic ratio” medications such as oxcarbazepine, although two carbamazepine studies are supportive. Most patients can successfully initiate therapy with generic AEDs and can safely switch from brand-name to generic AEDs (and sometimes back again). The FDA, however, has not shown safety in generic-to-generic switches, which could potentially cause drug concentration changes of up to 40%. Less expensive generic formulations will soon be available for most of the “second generation” AEDs—zonisamide, for example, recently had 17 generic formulations approved in the United States—providing substantial savings in health care costs.
In summary, although generic AEDs are generally safe and effective for most patients, the current bioequivalence standards may not be sufficient for certain patient populations and for certain drugs, requiring vulnerable patients to be monitored very carefully when converting to generic AEDs. The adequacy or inadequacy of FDA bioequivalence standards for AEDs has not yet been well evaluated with large, well-controlled studies.
Similar content being viewed by others
References and Recommended Reading
O’Brien TJ, Cascino GD, So EL, Hann DR: Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology 1998, 51:1034–1039.
Lesser RP, Krauss G: Buy some today: Can generics be safely substituted for brand-name drugs? Neurology 2001, 57:571–573.
Bialer M: Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia 2007, 48:1825–1832.
Liow K, Barkley GL, Pollard JR, et al.: Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007, 68:1249–1250.
US Food and Drug Administration (CDER): Office of Generic Drugs—What are generic drugs? http://www.fda.gov/cder/ogd/index.htm#introduction. Accessed December 12, 2007.
Castle S, Kanter J: European antitrust regulators raid large drug makers. New York Times. January 17, 2008. http://www.nytimes.com/2008/01/17/business/worldbusiness/17compete.html?_r=2&sq=genericdrugs. Accessed March 19, 2008.
Teva Announces Settlement Of Lamictal Litigation With GlaxoSmithKline [press release]. Jerusalem, Israel: Teva Pharmaceutical Industries Ltd; 2005. http://www.tevapharm.com/pr/2005/pr_513.asp. Accessed January 31, 2008.
US Food and Drug Administration (CDER): Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.fda.gov/cder/ob/default.htm. Accessed January 31, 2008.
US Food and Drug Administration (CDER): Generic drugs: questions and answers. http://www.fda.gov/cder/consumerinfo/generics_q&a.htm. Accessed December 12, 2007.
Niazi SK: Handbook of bioequivalence testing. New York: Informa Healthcare USA; 2007: 1–44.
Hauser WA, Annegers JF, Rocca WA: Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996, 71:576–586.
Gidal BE: Antiepileptic drug formulation and treatment in the elderly: biopharmaceutical considerations. Int Rev Neurobiol 2007, 81:299–311.
Cloyd JC, Marino S, Birnbaum AK: Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. Int Rev Neurobiol 2007, 81:201–210.
Collins NS, Shapiro RA, Ramsay RE: Elders with epilepsy. Med Clin North Am 2006, 90:945–966.
Oles KS, Penry JK, Smith LD, et al.: Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 1992, 42:1147–1153.
Silpakit O, Amornpichetkoon M, Kaojarern S: Comparative study of bioavailability and clinical efficacy of carbamaze pine in epileptic patients. Ann Pharmacother 1997, 31:548–552.
Wilder BJ, Leppik I, Hietpas TJ, et al.: Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. Neurology 2001, 57:582–589.
Wilner AN: Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004, 5:995–998.
US Food and Drug Administration (CDER): Therapeutic equivalence of generic drugs: response to National Association of Boards of Pharmacy: Immediate release solid oral dosage forms: Scale-up and postapproval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. http://www.fda.gov/cder/guidance/cmc5.pdf. Accessed March 19, 2008.
Perucca E: Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001, 15:405–417.
Benet LZ: Why highly variable drugs are safer. Presentation to the FDA Advisory Committee for Pharmaceutical Science; October 6, 2007; Rockville, MD. www.fda.gov/ohrms/dockets/ac/06/slides/2006-4241s2_2.ppt. Accessed March 19, 2008.
Oxcarbazepine [package insert]. East Hanover, NJ: Novartis Pharmaceuticals: 2007.
Williams RL, for Center for Drug Evaluation and Research: Therapeutic equivalence of generic drugs: response to National Association of Boards of Pharmacy, April 16, 1997. http://www.fda.gov/cder/news/ntiletter.htm. Accessed March 19, 2008.
Hauck WW, Anderson S: Measuring switchability and prescribability: When is average bioequivalence sufficient? J Pharmacokinet Biopharm 1994, 22:551–564.
Miller AD, Krauss GL, Hamzeh FM: Improved CNS tolerability following conversion from immediate-to extended-release carbamazepine. Acta Neurol Scand 2004, 109:374–377.
Nightingale SL for Center for Drug Evaluation and Research: Therapeutic equivalence of generic drugs: letter to health practitioners, January 28, 1998. http://www.fda.gov/cder/news/nightgenlett.htm. Accessed March 19, 2008.
Mikati M, Bassett N, Schacter S: Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Epilepsia 1992, 33:359–365.
Makus KG, McCormick J: Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007, 29:334–341.
Burkhardt RT, Leppik IE, Blesi I, et al.: Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004, 63:1494–1496.
Andermann F, Duh MS, Gosselin A, Paradis PE: Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007, 48:464–469.
Aldenkamp AP, Rentmeester T, Hulsman J, et al.: Pharma co kinetics and cognitive effects of carbamazepine formulations with different dissolution rates. Eur J Clin Pharmacol 1998, 54:185–192.
Perucca E, Albani F, Capovilla G, et al.: Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 2006, 47:16–20.
Kwan P, Brodie MJ: Effectiveness of the first antiepileptic drug. Epilepsia 2001, 42:1255–1260.
Hartley R, Aleksandrowicz J, Ng PC, et al.: Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? Br J Clin Pharmacol 1990, 44:270–227.
Berg MJ: What’s the problem with generic antiepileptic drugs? A call to action. Neurology 2007, 68:1245–1246.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shaw, S.J., Krauss, G.L. Generic antiepileptic drugs. Curr Treat Options Neurol 10, 260–268 (2008). https://doi.org/10.1007/s11940-008-0029-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-008-0029-6